Below you'll find a list of all posts from September, 2016
In-house biomanufacturing is costly. Besides the heavy infrastructure investment required, the need to efficiently manage talent, capacity, financial resources and quality often encourages pharma companies to consider outsourcing as an alternative. However, despite the growing number of CMO and CDMO within China, the availability of CMO providing high quality yet affordable services is lagging way behind the amount of demand within …
The biopharma industry in Asia is an exciting one. Despite uncertainty caused by a fragmented marketplace and different regulatory systems, innovators constantly overcome market challenges and produce useful inventions which brings the development of the industry to the next greater level. Among these is Immunwork, a Taiwanese biotech company which created an invention, T-E™ , a molecule containing both targeting (T) …
Drug discovery is a high risk, high return business. Despite the intrinsic risks, pharma companies continue to invest heavily in R&D to improve the quality of life of patients in needs of treatment. While capital is important in R&D outcomes, innovation-based organisations need to understand the best model to adopt to speed up the process in bringing discoveries to useful commercial …
At BioPharma Asia 2017, we invite 40 Asia biotech companies to present their innovative offerings in our new Biotech Innovation track. Among the participating companies is BioValence, Malaysia. Prior to the event, we asked EngHung Ung, CTO of BioValence to give you a preview on what you will expect to hear from them at the event. Q: Who is Biovalence and how is it disrupting the …
